Nonclinical and Clinical Experiences with CPP-Based Self-Assembling Peptide Systems in Topical Drug Development

  • Jacob M. Waugh
  • Jane Lee
  • Michael D. Dake
  • Dan Browne
Part of the Methods in Molecular Biology book series (MIMB, volume 683)


Considerations in rational designs of CPP-based transcutaneous delivery systems are described. Impact of design considerations of nonclinical and clinical results are presented in detail.

Key words

Botulinum toxin Lateral canthal lines Hyperhidrosis TAT Ionic 


  1. 1.
    Scott, A.B. (1981) Botulinum toxin injection of eye muscles to correct strabismus Trans Am Ophthalmol Soc 79, 734–770.PubMedGoogle Scholar
  2. 2.
    Hallett, M. (1999) One man’s poison-clinical applications of botulinum toxin N Engl J Med 341, 118–120.CrossRefPubMedGoogle Scholar
  3. 3.
    Spencer, J.M. (2002) Botulinum Toxin B. The new option in cosmetic injection J Drugs Dermatol 1, 17–22.PubMedGoogle Scholar
  4. 4.
    Carruthers, A. and Carruthers, J. (2005) Botulinum toxin type A J Am Acad Dermatol 53, 284–290.CrossRefPubMedGoogle Scholar
  5. 5.
    Carruthers, J. and Carruthers, A. (2007) The evolution of botulinum toxin type A for cosmetic applications J Cosmet Laser Ther 9, 186–192.CrossRefPubMedGoogle Scholar
  6. 6.
    Carruthers, J. and Carruthers, A. (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin J Dermatol Surg Oncol 18,17–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Carruthers, J., Fagien, S., Matarasso, S.L., and BOTOX Consensus Group. (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics Plast Reconstr Surg 114:1S–22S.CrossRefPubMedGoogle Scholar
  8. 8.
    The American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data Bank. 2006 statistics. Accessed 30 March 2007.
  9. 9.
    Bushara, K.O., Park, D.M., Jones, J.C., and Schutta, H.S. (1996) Botulinum toxin-a possible new treatment for axillary hyperhidrosis Clin Exp Dermatol 21, 276–278.CrossRefPubMedGoogle Scholar
  10. 10.
    Schnider, P., Binder, M., Berger, T., and Auff, E. (1996) Botulinum A toxin injection in focal hyperhidrosis Br J Dermatol 134, 1160–1161.CrossRefPubMedGoogle Scholar
  11. 11.
    Naumann, M., Hofmann, U., Bergmann, I., Hamm, H., Tiyka, K.V., and Reiners, K. (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin Arch Dermatol 134, 301–304.CrossRefPubMedGoogle Scholar
  12. 12.
    Heckmann, M., Ceballos-Baumann, A.O., and Plewig, G. (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating) N Engl J Med 344, 488–493.CrossRefPubMedGoogle Scholar
  13. 13.
    Naumann, M. and Lowe, N.J. (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial BMJ 323, 596–599.CrossRefPubMedGoogle Scholar
  14. 14.
    Lowe, N.J., Lask, G., Yamauchi, P., and Moore, D. (2002) Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet J Am Acad Dermatol 47, 834–840.CrossRefPubMedGoogle Scholar
  15. 15.
    Lowe, N.J., Ascher, B., Heckmann, M., Kumar, C., Fraczek, S., and Eadie, N. (2005) BOTOX Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet Dermatol Surg 31, 257–262.CrossRefPubMedGoogle Scholar
  16. 16.
    Matarasso, S.L. and Matarasso, A. (2001) Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids Plast Reconstr Surg 108, 208–214.CrossRefPubMedGoogle Scholar
  17. 17.
    Allergan, Inc. (2006) BOTOX Cosmetic (Botulinum Toxin Type A) Prescribing Information. Allergan, Inc., Irvine, CAGoogle Scholar
  18. 18.
    Aoki, K.R. and Guyer, B. (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions Eur J Neurol 8, 21–29.CrossRefPubMedGoogle Scholar
  19. 19.
    Grumelli, C., Verderio, C., Pozzi, D., Rossetto, O., Montecucco, C., and Matteoli, M. (2005) Internalization and mechanism of action for clostridial toxins in neurons Neurotoxicology 26, 761–767.CrossRefPubMedGoogle Scholar
  20. 20.
    Dutton, J.J. and Fowler, A.M. (2007) Botulinum toxin in ophthalmology Surv Ophthalmol 52, 13–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Ford, K.G., Souberbielle, B.E., Darling, D., and Farzaneh, F. (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8, 1–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Aoki, K.R. (2001) A comparison of the safety margins of botulinum toxin serotypes A, B, and F in mice Toxicon 39, 1815–1820.CrossRefPubMedGoogle Scholar
  23. 23.
    Glogau, R.G. (2007) Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study Dermatol Surg 33, S76–S80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jacob M. Waugh
    • 1
  • Jane Lee
    • 1
  • Michael D. Dake
    • 2
  • Dan Browne
    • 1
  1. 1.Revance Therapeutics IncNewarkUSA
  2. 2.Cardiothoracic Surgery Department, Falk Cardiovascular Research CenterStanford University School of MedicineStanfordUSA

Personalised recommendations